中国药业2024，Vol.33Issue(12)：45-49,5.DOI:10.3969/j.issn.1006-4931.2024.12.011
3类心血管疾病治疗药物肾脏安全性药物警戒研究
Kidney Safety of Three Types of Drugs for Cardiovascular Disease:A Pharmacovigilance Study
摘要
Abstract
Objective To provide a reference for the selection of drugs for cardiovascular disease(CVD)in clinical practice.Methods The kidney injury-related adverse drug events(ADEs)induced by angiotensin receptor-neprilysin inhibitors(ARNIs),angiotensin-converting enzyme inhibitors(ACEIs)and angiotensin Ⅱ receptor blockers(ARBs)in the FDA Adverse Event Reporting System(FAERS)from 2004 to 2021 were searched,the reporting odds ratio(ROR)and information component(IC)methods were used to mine and analyze ADE signals.Results There were 13 155,12 623 and 2 411 cases of kidney injury induced by ACEIs,ARBs and ARNIs respectively.Positive signals for acute kidney injury(AKI)and chronic kidney disease(CKD)were detected in all the three drugs.Compared with those induced by ACEIs and ARBs,the positive signals of AKI and CKD induced by ARNIs were stronger,the mortality composition ratios of patients with AKI(18.31%vs.13.05%,P<0.05;18.31%vs.10.53%,P<0.05)and CKD(23.50%vs.19.78%,P<0.05;23.50%vs.11.41%,P<0.05)induced by ARNIs were significantly higher.Conclusion Compared with ACEIs and ARBs,ARNIs may have a higher risk of AKI and CKD.关键词
血管紧张素受体脑啡肽酶抑制剂/血管紧张素转化酶抑制剂/血管紧张素Ⅱ受体拮抗剂/肾损伤/药品不良事件/美国食品和药物管理局不良反应事件报告系统/用药安全/信号挖掘Key words
angiotensin receptor-neprilysin inhibitor/angiotensin-converting enzyme inhibitor/angiotensin Ⅱ receptor blocker/kidney injury/adverse drug event/FDA Adverse Event Reporting System/medication safety/signal mining分类
医药卫生引用本文复制引用
方振威,柏杨,王棋,李玉文..3类心血管疾病治疗药物肾脏安全性药物警戒研究[J].中国药业,2024,33(12):45-49,5.基金项目
国家重点研发计划课题[2020YFC2008302]. （）
